This open-label, multi-center study will compare the bioavailability of RoActemra/Actemra (tocilizumab) administration by auto-injector versus pre-filled syringe in healthy volunteers. Healthy volunteers will receive a single dose of RoActemra/Actemra (tocilizumab). The anticipated time of study duration is 28 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
239
Single dose administration with pre-filled syringe
Single dose administration with auto-injector
Unnamed facility
Montpellier, France
Unnamed facility
Rennes, France
Area under the plasma concentration versus time curve (AUC) of RoActemra/Actemra
Time frame: 21 days
Peak plasma concentration of RoActemra/Actemra
Time frame: 21 days
Safety (Incidence of adverse events)
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.